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Abstract
Venous thromboembolism (VTE) is associated with high recurrence, mortality, and cost burden. Direct oral anticoagulants
(DOACs) are currently used for VTE treatment, and they offer more benefits over warfarin, despite being more expensive. There
is no consensus on the most cost-effective DOAC agent, especially in VTE. This systematic review aims to summarize the
comparative cost-effectiveness studies and their impact among DOACs in the treatment of VTE. Literature systematic review of
PubMed, Embase, and EconLit was conducted in February 2018 to identify all cost-effectiveness studies of DOAC for the
treatment and prevention of VTE. Two independent investigators systematically collected search results and assessed the quality
of the studies. The search identified 7 articles, all of which had dabigatran and rivaroxaban as comparators, 6 of which also included
apixaban, and 2 of which also had edoxaban. Results of 3 articles concluded that apixaban is a dominant strategy compared to
other DOACs in terms of Incremental Cost-Effectiveness Ratio (ICER) in the treatment and prevention of recurrent VTE. One
article compared rivaroxaban and dabigatran, with the latter dominating rivaroxaban in terms of ICER. Compared to other
DOACs, 2 articles reported apixaban being associated with highest annual total medical cost avoidance of US$4244 and US$4440
per patient-year (ppy), respectively. One article reported that apixaban had the highest annual total medical cost differences of
US$918 ppy compared to other DOACs. This systematic review demonstrates that apixaban is considered a cost-effective
strategy for VTE treatment and prevention of recurrent VTE.
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Background
Venous thromboembolism (VTE) is considered a serious and
potentially life-threatening medical condition.1 The annual
incidence of VTE (deep venous thrombosis [DVT] and pul-
monary embolism [PE]), in Europeans as an example, is esti-
mated to be 104 to 183 per 100 000 person-years.2 Incidence
rates of DVT (without PE) and PE (without DVT) are 45 to 117
and 29 to 78 per 100 000 person-years, respectively.3-6 These
rates are higher among the African American population and
lower among the Native American population, Asian, and
Asian American populations.2
Risk factors for VTE include advanced age, overweight,
hospitalization, immobility, especially after total hip
replacement (THR) and total knee replacement (TKR) surgeries,
active cancer, trauma, fractures, and superficial vein thrombosis.7
Before 2010, the mainstay pharmacologic prophylaxis and
treatment of VTE were warfarin, heparin, low-molecular-
weight heparin (LMWH), and fondaparinux.8 Since the intro-
duction of the first direct oral anticoagulant (DOAC), that is,
dabigatran, in 2010, the anticoagulation landscape has started
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to change. Since then, several other DOACs have been
approved, including rivaroxaban, apixaban, edoxaban, and
betrixaban. Direct oral anticoagulants offer potential advan-
tages compared to warfarin including fixed dosing, lack of food
and drug interactions, minimal need for monitoring, and super-
ior safety profile. Direct oral anticoagulants, however, are asso-
ciated with an increased risk of gastrointestinal adverse drug
reactions (dabigatran and rivaroxaban), lack of an easily mon-
itored surrogate marker, and higher cost.9
Numerous studies and systematic reviews have compared
DOACs with warfarin in terms of their cost-effectiveness and
cost benefit.10-18 Apart from 1 report that was conducted on
studies published till 2014,19 there have been no updated sys-
tematic reviews comparing among DOACs (either directly or
indirectly) in the prevention and treatment of VTE. In this
systematic review, we aim to explore studies comparing the
cost-effectiveness of DOACs in the treatment and prevention
of VTE.
The objective of this systematic review is to summarize and
compare the main cost-effectiveness outcomes in studies com-
paring DOAC agents in the prevention and treatment of VTE.
This will answer the question about which of the DOACs is the
most cost-effective in the prevention and treatment of VTE.
Methods
The Literature Search
A systematic search of the literature was conducted via the
following databases: PubMed, Embase, and EconLit. The
search strategy followed the PICO format. As an example,
within the PubMed database, the population was: venous
thromboembolism, VTE, deep venous thrombosis, DVT, pul-
monary embolism, PE, atrial fibrillation, AF, stroke; the inter-
vention/comparator was: anticoagulants, rivaroxaban,
dabigatran, apixaban, edoxaban, direct oral anticoagulant,
novel oral anticoagulant, DOAC, NOAC; the outcome was
cost-effectiveness, cost-benefit, cost analysis, economics, cost
of illness, cost savings, cost control. A similar search strategy
was used with the other search databases. Key words were
customized to database-specific indexing terms, for example,
the use of MeSH terms. As appropriate, the terms and their
alternatives were combined with Boolean connectors (AND/
OR/NOT). In addition to the electronic search, we performed
a manual search of bibliographies and references of identified
articles and cost-related specific issues in journals. The gray
literature search also included preliminary progress and
advanced reports, theses, conference proceeding, technical
reports, and guidelines, in addition to searching indexing terms
via the Google search engine. A search protocol of the systema-
tic review was developed and registered in PROSPERO (ID#
CRD42018098705).
Study Types
Any cost-effectiveness study comparing DOACs in the treat-
ment and/or prevention of VTE.
Participants
Patients treated with DOACs for the treatment and/or preven-
tion of VTE.
Eligibility Criteria
Studies were considered eligible for this review if they were
pharmacoeconomic studies comparing more than 1 DOAC in
adults (>18 years old) for the prevention or treatment of VTE,
including DVT and/or PE. We included only comparative
studies in the English language, of human species, and in
journal articles with full-text availability from January 1,
2010 (the year of the first approved DOAC]dabigatran[) to
February, 2018 (the date this review was conducted). Exclu-
sion criteria include reviews, noncomparative studies, and
studies with a single DOAC alone as a comparator or against
warfarin. The selection of articles was conducted via 2 inde-
pendent reviewers by the initial screening of titles/abstracts of
articles, before a follow-up screening of the full text. When
disagreements occurred, articles were discussed with a third
reviewer until consensus.
Outcome Measures
The outcome measure of interest is the observed trends in
relation to the comparative economic outcomes of the DOAC
agents, dabigatran, rivaroxaban, apixaban, edoxaban, and
betrixaban, including total cost, cost avoidance, and the incre-
mental cost-effectiveness ratio (ICER). Also a comparative
outcome of interest is when a DOAC is both more effective
and less costly than another (ie, dominant DOAC), or the
converse (ie, dominated DOAC), in which case the ICER
becomes meaningless.
Data Extraction and Synthesis
A data extraction tool was developed and pilot tested using a
sample of the eligible studies (n ¼ 3). The extracted data
includes the DOACs compared, country, disease states, elig-
ibility criteria, primary and secondary outcomes (efficacy and
pharmacoeconomic), funding, the comparative model used,
type of cost-effectiveness analysis, uncertainty tests, and sum-
mary of findings. If any of the information was missing, the
corresponding author of a particular article was contacted. Two
reviewers independently extracted data from included articles,
ensuring data reliability and trustworthiness. A consensus was
reached whenever differences occurred.
Assessment of Quality of Studies
As with the study inclusion and data extraction, the quality of
articles was assessed by 2 independent reviewers who critically
appraised the included articles to assess the risk of bias and
methodological quality. For the purpose, the Quality of Health
Economic Studies (QHES) tool20 was utilized. The QHES
includes 16 questions, and each question has a different score
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ranging from “0” to “9,” with the total of all questions scores
adding to 100 points. The interpretation of a QHES score was
as per 1 of 4 categories of quality, that is, good, fair, poor, and
extremely poor, associated with the scores 75 to 100, 50 to 74,
25 to 49, and 0-24, respectively.21-24 A third independent
reviewer would contribute whenever a disagreement occurs.
Only articles with fair or good methodological quality were
included in this review.22 The systematic review followed the
Preferred Reporting Items for Systematic reviews and Meta-
Analyses (PRISMA) guideline, including a 27-item checklist
of essential items to be reported in a systematic review.25
Results
Study Selection
Of a total of 704 retrieved articles, 7 articles met the inclusion/
exclusion criteria. Search results are illustrated in Figure 1.
Characteristics of the Included Articles
All studies in this review included dabigatran and rivaroxaban
as part of the DOACs compared.26-32 Apixaban was included in
6 studies and edoxaban was included in 2 studies only. Further-
more, because of how recently approved it is, betrixaban was
not included in any of the studies. The majority of the articles
used Markov modeling that follows cohorts of patients over
follow-up periods of 3, 6, and 12 months as well as the lifetime
of patients, with 3- or 6-month transitional model cycles. The
only exception was the study by Amin et al, where a non-
Markov simulation was used to follow-up patients over 1 year
from having recurrent VTE.
In general, all studies used pivotal trials versus warfarin as
primary sources of clinical inputs for dabigatran (RE-COVER,
RE-COVER II, and RE-MED),33-35 rivaroxaban (EINSTEIN,
EINSTEIN-DVT, and EINSTEIN-PE),36-38 apixaban
(AMPLIFY and AMPLIFY-EXT)39,40 and edoxaban
(Hokusai-VTE).41 The modeled clinical events in included
cost-effectiveness studies were therefore fairly consistent.
Clinical efficacy and safety events included recurrent VTE and
VTE-related death, minor bleeding, major bleeding, and clini-
cally relevant non-major bleeding (CRNMB). Other events
were chronic thromboembolic pulmonary hypertension, post
thromboembolic syndrome, and intracranial bleed. These clin-
ical events were evaluated over patient lifetime,26,27,29,32
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except for Amin et al where the events were evaluated on
annual basis.28,30,31
Among the 7 included studies, 3 were conducted in the United
States,28,30,31 2 in the United Kingdom,26,32 and 2 in Canada.27,29
The most common measure for the cost-effectiveness evaluation
was cost/ICAR (QALY), and it was used in 4 studies.26,27,29,32
Annual totalmedical cost avoidancewas used in 2 studies28,30 and
annual total medical cost differences in 1 study.31 In regard to
funding, 6 studies were funded by drug sponsors,26-28,30-32 while
no fundingwas receivedbyAlSaleh et al. Table 1 summarizes the
general characteristics of the included articles.
Efficacy End Point Results
Different measures were used in different studies to assess the
efficacy of each DOAC. Three studies reported differences in
absolute clinical event rates versus placebo, control, and war-
farin.28,30,31 Two studies reported results in terms of a number of
events among a cohort of 10 000 patients.27,32 One study
reported fatality rates and one study reported relative risk (RR)
of recurrent VTE.26,29 Most articles conducted univariate (1-
way) sensitivity analysis to determine the impact of every single
parameter used in the analysis model on the total medical cost
estimated through the model. Amin et al concluded in all of their
3 studies that variations in both VTE and major bleeding had the
highest impact on medical cost differences in terms of total
medical cost differences and avoidance between DOACs, stan-
dard therapy, and placebo.28,30,31 Al Saleh et al reported that
fatality rates in the short run and pharmaceutical care were the
highest determinants to uncertainty in the conducted analysis.29
Quon et al concluded that both major and CRNMB events were
the main drivers for apixaban being the cost-effective choice
among other DOACs.27 Lanitis et al reported that apixaban
would not be considered a dominant choice when the differ-
ential price between other DOACs and apixaban increased and
when the relative risk of recurrent VTE is reduced for rivarox-
aban versus apixaban from a baseline 1.08 to 0.69.32 Table 2
summarizes the efficacy end points for each DOAC in terms of
recurrent VTE.
Cost-Effectiveness Results
Measures used to assess the cost-effectiveness of DOACs were
not the same among the different studies. The majority of stud-
ies (n ¼ 4) mostly used the cost/QALY measure, including the
total costs calculations.26,27,29,32 Jurgin et al reported that for
6-month therapy with dabigatran compared to 3-, 6-, and
12-month treatment with rivaroxaban for VTE treatment and
extended anticoagulation and index DVT and PE treatment
among a cohort of 10 000 patients, dabigatran is dominant over
rivaroxaban, having lower cost and higher QALY, in all these
settings. A similar trend was observed in their study evaluating
the VTE treatment and extended anticoagulation indication,
and for index DVT and PE treatment in 6-month therapy
among a cohort of 10 000 patients for both dabigatran and
rivaroxaban, where dabigatran also dominates rivaroxaban in
all these settings. In a 6-month evaluation of VTE treatment
over a patient’s lifetime, Lanitis et al reported apixaban to be
dominant over both rivaroxaban and LMWH/dabigatran, with
total costs of £4696, £4731, and £4792 with each, respectively.
Apixaban did not dominate LMWH/warfarin, with apixaban
costing £2520 over the latter per QALY. In overall, the per-
patient treatment, administration, and monitoring costs were
lower with apixaban by £11 and £45 compared to rivaroxaban
and LMWH/dabigatran, respectively. In the study by Quon
et al, the total lifetime costs per patient with up to 18 months
of DOACs or 6 months of enoxaparin/warfarin were reported.
Apixaban had lower costs and longer survival or higher
QALYs compared to enoxaparin/warfarin, rivaroxaban, and
dabigatran. Al Saleh et al reported the comparative cost/QALY
among the therapies LMWH/VKA, LMWH/dabigatran, rivar-
oxaban, and apixaban. Apixaban dominated other DOACs with
an ICER of US$84.08 relative to LMWH/VKA. Furthermore,
at a discount rate of 0%, apixaban dominates other strategies
Table 1. General Characteristics of the Included Articles.
Author Comparators Setting Year Analysis Type Population
Al Saleh et al29 Dabigatran, Rivaroxaban, Apixaban,
Warfarin
Canada 2017 ICER (Cost/QALY) Treatment of DVT and PE
in outpatient settings
Amin et al30 Dabigatran, Rivaroxaban, Apixaban
(2.5-5 mg)
United States 2014 Annual total medical cost avoidance Extended treatment of VTE
Amin et.al31 Dabigatran, Rivaroxaban, Apixaban,
Edoxaban
United States 2014 Annual total medical cost
differences
Treatment of VTE
Amin et al28 Dabigatran, Rivaroxaban, Apixaban,
Edoxaban
United States 2015 Annual total medical cost
avoidances
Treatment of VTE
Jurgin et al26 Dabigatran, Rivaroxaban United
Kingdom
2015 ICER (Cost/QALY) Treatment and extended
treatment of VTE
Lanitis et al32 Dabigatran, Rivaroxaban, Apixaban,
Warfarin
United
Kingdom
2016 ICER (Cost/QALY) Initial treatment of VTE
Quon et al27 Dabigatran, Rivaroxaban, Apixaban,
Warfarin
Canada 2016 ICER (Cost/QALY) Treatment and prevention
of recurrence of VTE
Abbreviations: DVT, deep venous thrombosis; ICER, incremental cost-effectiveness ratio; PE, pulmonary embolism; QALY, quality-adjusted life-years;
VTE, venous thromboembolism.
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and with 3% discount rate, apixaban dominates other DOACs
with an ICER of US$36.79 relative to LMWH/VKA. In a dif-
ferent analysis of 3 months of therapy and for lifetime duration
of the anticoagulation therapy, apixaban dominated other
DOACs with an ICER relative to LMWH/VKA of
US$7379.66 and US$174 614.23, respectively. However, with
a 12-month therapy, apixaban dominated all other treatments.
Two studies reported the annual total medical cost avoidance
as the primary measure.28,30 Amin et al reported the annual total
medical cost avoidance associated with DOAC use compared to
placebo asUS$2794,US$2948,US$4249, andUS$4244 ppy for
patients with VTE treated with dabigatran, rivaroxaban, apixa-
ban 2.5 mg, and apixaban 5 mg, respectively, with the highest
cost avoidance associated with apixaban 2.5 mg followed by
apixaban 5 mg. A similar trend was also observed in a different
study of theirs, where they reported annual total medical cost
avoidance for VTE treatment with DOACs versus warfarin ppy
as follows: US$572, US$2971, US$4440, and US$1957 with
dabigatran, rivaroxaban, apixaban, and edoxaban, respectively.
Reporting the total medical cost differences as the outcome
measure, in a third study of theirs, Amin et al reported that the
use of DOACs in comparison to standard therapy was associ-
ated with overall medical cost differences of US$146, US$482,
US$918, and US$344 for patient with VTE treated with dabi-
gatran, rivaroxaban, apixaban, and edoxaban, respectively,
with the highest cost differences associated with apixaban.
When treatment duration was normalized, the annual total
medical cost differences were US$153, US$454, US$1108, and
US$261 for a patient with VTE treated with dabigatran, rivar-
oxaban, apixaban, and edoxaban, respectively, also with the
highest cost differences associated with apixaban. Table 3
summarizes the time horizon, event of interest, comparators,
outcome measures, and results of the cost-effectiveness analy-
sis conducted in each article.
All studies performed probabilistic sensitivity analysis to
ensure the robustness of their results. Jurgin et al reported that
at £20 000 willingness to pay threshold (WTP), dabigatran ther-
apy compared to 3-, 6-, and 12-month therapy of rivaroxaban had
61% and 88% probability of being good value for money in the
treatment and extended anticoagulationofVTE, respectively, and
62% and 62% probability in DVT and PE, respectively. Further-
more, Lanitis et al reported that apixaban was also a dominant
choice in 87% of the trials compared to rivaroxaban and in 98% of
the trials compared to LMWH/dabigatran. Furthermore, in com-
parison to LMWH/VKA, apixaban was found to be the cost-
effective choice in 100% of trials with an ICER of < £20 000 per
QALY. Moreover, Quon et al reported that at WTP of US$5000
per QALY, apixaban had the highest probability of being cost-
effective compared to dabigatran, rivaroxaban, and warfarin. At
WTP of US$10 000 and US$50 000 for each additional QALY,
apixabanhad93.5% and97.7%probabilityofbeing themost cost-
effective choicecompared toother treatments.Aminet al reported
both univariate andmultivariate sensitivity analyses in all of their
3 studies. The results were also in favor of the original results with
apixaban being associated with the highest cost avoidance and
differences compared to dabigatran, rivaroxaban, and edoxaban.
Quality Assessment Results
The majority of studies were fair in quality, with none of the
studies performing poorly. Table 4 represents the results of the
quality assessment of the included articles.
Table 2. Recurrent VTE Efficacy End Point Results.
Author Measure Used Clinical Events Results
Al Saleh et al29 Fatality rates Recurrent DVT/PE ¼ 2.55%, 1.88%, 1.78%, and 2.14% for dabigatran þ LMWH,
rivaroxaban, apixaban, and VKA þ LMWH, respectively
Amin et al30 Differences in absolute clinical
event rates
Recurrent VTE ¼ 5.15% (5.48% to 4.19%)a, 5.74% (6.43% to 4.31%)a, 7.14%
(7.84% to 5.90%)a, 7.08% (7.84% to 5.81%)a for dabigatran, rivaroxaban,
apixaban 2.5 mg, and apixaban 5 mg, respectively (vs placebo)
Amin et al31 Differences in absolute clinical
event rates
Recurrent VTE/VTE related death ¼ 0.20% (0.52% to 1.22%)a, 0.23% (0.78% to
0.44%)a, 0.43% (1.08% to 0.49%), a and 0.34% (0.78% to 0.27%)a for dabigatran,
rivaroxaban, apixaban 2.5 mg and apixaban 5 mg, respectively (vs control)
Amin et al28 Differences in absolute clinical
event rates
Recurrent VTE among patients with VTE ¼ 1.02% (2.69 to 6.35%)a, 1.23% (3.81% to
2.13%)a, 1.80% (4.48% to 2.02%)a, and 2.02% (4.48% to 1.57%)a for dabigatran,
rivaroxaban, apixaban and edoxaban, respectively (vs warfarin)
Jurgin et al26 Relative risk (RR) Recurrent VTE (3, 6, 12 months)¼ RR for rivaroxaban vs dabigatran¼ 0.83 (0.46 to 1.49)a
Recurrent VTE (6 months) ¼ RR for rivaroxaban vs dabigatran ¼ 0.90 (0.53, 1.52)a
Lanitis et al32 Number of events among (cohort
of 10 000 patients)
Recurrent VTE/VTE-related death (6-month treatment over patient lifetime) ¼ 604, 601,
600, and 602 for dabigatran/LMWH, rivaroxaban, apixaban, and VKA/LMWH,
respectively
Quon et al27 Number of events (cohort of
10 000 patients)
Recurrent VTE events ¼ 520, 512, 521, and 607 for dabigatran, rivaroxaban, apixaban, and
enoxaparin/VKA, respectively, for up to 18 months treatment over patient life time with
DOACs or 6 months of enoxaparin/VKA
Abbreviations: DVT, deep venous thrombosis; LMWH, low-molecular-weight heparin; PE, pulmonary embolism; RR, relative risk; VKA, vitamin K antagonist; VTE,
venous thromboembolism.
a95% Confidence interval (CI).
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Discussion
To our best knowledge, this is the first systematic review that
summarizes cost-effectiveness studies comparing among
DOACs in VTE, either directly or indirectly. There is lack of
standardization on how systematic reviews of cost-effectiveness
studies are to be conducted, and the current study achieves
its objectives of comparatively summarizing the cost-
effectiveness evaluations among DOACs for the purpose of
health-care providers and decision makers in practices,
including formulary decisions. It seems that the higher cost
of DOACs was dominated by the value of their advantages
of the minimized need for monitoring and the superior effi-
cacy and safety profiles.
In relation to the results of efficacy end points, as seen in
Table 2, the majority of the studies (n ¼ 5) concluded that
apixaban was associated with the least number of clinical
events in terms of recurrent VTE, compared to the other
DOACs. Amin et al, however, reported that edoxaban was
superior to apixaban in terms of the reduced recurrent VTE
rate in the general population, with both showing superiorities
in efficacy over the dabigatran and rivaroxaban. In the study by
Quon et al, only investigating dabigatran and rivaroxaban, the
latter was associated with superior efficacy compared to
Table 3. General View of the Model Structure and Events Used in the Included Articles.
Author Time Horizon Event of Interest Comparators Outcome Measure Results
Al Saleh et al29 Each cycle ¼ 6 m
Follow-up ¼ 6 m,
12 m
Life-time
Recurrent DVT and PE
and major bleeding
Dabigatran, rivaroxaban,
apixaban, warfarin
ICER (Cost/QALY) Apixaban dominates other
DOACs in 3, 6, aand
12 months and lifetime
treatment duration
Amin, et.al30 1 year Recurrent VTE, major
bleeding and CRNMB
Dabigatran, rivaroxaban,
apixaban (2.5-5 mg)
Annual total medical
cost avoidance
Apixaban 2.5 mg dominates
other DOACs with
US$4249 cost avoidance
compared to placebo
Amin, et.al31 1 year Recurrent VTE, major
bleeding, CRNMB and
other minor bleeding
Dabigatran, rivaroxaban,
apixaban, edoxaban
Annual total medical
cost differences
Apixaban dominates other
DOACs with US$918 cost
difference compared to
standard therapy
Amin, et.al28 1 year Recurrent VTE and
major bleeding
Dabigatran, rivaroxaban,
apixaban, edoxaban
Annual total medical
cost avoidances
Apixaban dominates other
DOACs with cost
avoidance of US$2971 per
patient year (ppy),
compared to warfarin
Jurgin et al26 Each cycle ¼ N/A
Follow-up¼ 3 m,
6 m, 12 m and
Life-time
Recurrent VTE, MCRBE,
CTEPH, and PTS
Dabigatran, rivaroxaban ICER (Cost/QALY) Dabigatran dominates
rivaroxaban in all treatment
settings
Lanitis, et.al32 Each cycle ¼ 3 m
Follow-up ¼ 3 m,
6 m, 12 m
Life-time
Recurrent VTE, major
bleeding, CTEPH,
CRNM, Death
Dabigatran, rivaroxaban,
apixaban, warfarin
ICER (Cost/QALY) Apixaban dominates
rivaroxaban and LMWH/
dabigatran in 6 months
treatment duration and
with ICER of US$2520
relative to LMWH/VKA
Quon et al27 Cycle ¼ 3 m
Follow-up¼ 3 m,
6 m, 12 m
Life-time
Recurrent PE and DVT,
IC, non-IC major
bleed, CRNM,
treatment
discontinuation,
CTEPH, PTS, death, or
no event
Dabigatran, rivaroxaban,
apixaban, warfarin
ICER (Cost/QALY) Apixaban dominates
dabigatran, rivaroxaban
with treatment duration up
to 18 months and with
ICER of US$4827.78
relative to enoxaparin/VKA
Abbreviations: CRNMB, clinically relevant non-major bleeding; CTEPH, chronic thromboembolic pulmonary hypertension; DOAC, Direct oral anticoagulants;
DVT, deep venous thrombosis; IC, intracranial bleed; ICER, incremental cost-effectiveness ratio; MCRBE, major and clinically relevant bleeding event;
PE, pulmonary embolism; PTS, post thromboembolic syndrome; QALY, quality-adjusted life-years; VTE, venous thromboembolism.
Table 4. Quality Assessment, QHES Tool.
Author Score
Overall
Assessment Grading Criteria
Al Saleh et al29 82 Good Quality Good Quality ¼ 76-100
points
Fair Quality ¼ 51-75
points
Poor Quality ¼ 0-50
points
Amin et al30 74 Fair Quality
Amin et al31 71 Fair Quality
Amin et al(2015)28 71 Fair Quality
Jurgin et al26 89 Good Quality
Lanitis et al32 88 Good Quality
Quon et.al27 71 Good Quality
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dabigatran. However, in all other included studies (n ¼ 6),
dabigatran had superior efficacy over rivaroxaban. In sum-
mary, edoxaban appears to be second to apixaban in efficacy,
followed by dabigatran and then rivaroxaban. In relation to the
efficacy against initial treatment and extended treatment of
VTE, apixaban was demonstrated in this review to be the most
efficacious, with a superior safety and efficacy profile, com-
pared to other DOACs. These results come in line with previ-
ous studies evaluating the safety and efficacy of DOACs in
different disease conditions.42-44 Important to note is that
results have to be interpreted cautiously giving that all com-
parative data are not based on head-to-head study sources and
were all performed using clinical events reported in the litera-
ture. These events were extracted from studies that compared
DOACs to the gold standard warfarin/LMWH. And to the best
of our knowledge, there are no real-world head-to-head data in
the VTE treatment/prophylaxis that compares DOACs in terms
of effectiveness and/or safety.
Results of the cost-effectiveness analyses are based on stud-
ies from 3 different countries (United States, United Kingdom,
and Canada), and they differ in the used economic model, study
perspective (ie, the adopted viewpoint of the analysis regarding
the type of included costs and effects; eg, society, payer, pro-
vider, and patient), comparators, acquisition costs, willingness-
to-pay threshold, and presentation of results as well as the
financial year of results. The variability in such important
methodological aspects of studies makes the generation of
cumulative quantitative evidence or summative cost values
nonfeasible for DAOCs. Descriptive study results, neverthe-
less, and based on the currently available evidence, show that
apixaban was the most cost-effective (dominant) option in
terms of annual total medical cost avoidance, savings ppy and
cost/QALY. In terms of VTE initial treatment, apixaban
showed favorable prevention of VTE recurrence and reduction
in bleeding events after 6 months of treatment, at a lower cost.
The major and CRNM bleeding events were also lower with
apixaban, compared to other DOACs, resulting in apixaban
being a more cost-effective treatment option compared with
other alternatives, including dabigatran and rivaroxaban. Riv-
aroxaban was inferior to apixaban but superior (cost-effective)
over edoxaban and dabigatran. Edoxaban was inferior to both
apixaban and rivaroxaban according to Amin et al, but it was
superior to dabigatran in terms of annual total medical cost
differences and avoidance per patient-year. Dabigatran was
dominated in almost all cost-effectiveness studies, except in
that by Jurgin et al, where it dominates rivaroxaban in terms
of cost/QALY.
More importantly, results in this review are consistent with
other reports in the literature, including systematic reviews,
cost-effectiveness analyses and meta-analyses that also com-
pared the cost-effectiveness among DOACs, and for stroke
prevention in patients with atrial fibrillation.11,12,14-16 An addi-
tional example of consistent results is a Monte-Carlo cost-
effectiveness simulation of rivaroxaban against apixaban,
where the former had the lowest cost compared to other
DOACs, while the latter had the highest QALYs and was con-
sidered the most cost-effective.45
This review includes several limitations. First, while the
search strategy did include gray literature, this did not include
nonpublished articles, which could have been of relevance.
Also, the search was language restricted, where relevant
articles could have been missed. Resources to translate non-
English articles, however, are not available to authors. Addi-
tional articles could have been identified in the literature with
the use of additional search engines. Here, nonetheless, it is
noted that the PubMed and Embase databases cover almost
80% of the literature, and with the utilization of EconLit as
well, the authors believe to have covered a representative
sample of literature.46 Additional articles could have also
been found with other key search terms and/or new combina-
tions of them. Here, of relevance, it is important to note that
we included “atrial fibrillation” and “stroke” in the search
terms, in case of having studies looking at VTE as a secondary
underlying indication to the stroke and atrial fibrillation. This
would help ensure the comprehensiveness of our search and
reduce the possibility of missing any potential articles. More-
over, 6 of the included studies in this review were industry
funded. A final limitation in the study is that the quality of
journals and their editorial requirements were not weighed
into the quality assessment.
Conclusion
Apixaban dominates other DOACs for the prevention and treat-
ment of VTE. In VTE extended treatment, apixaban was asso-
ciated with the highest cost avoidance mainly due to the
reduced rates of recurrent VTE and major bleeding compared
to other DOACs. The cost-effectiveness of apixaban is fol-
lowed by that of rivaroxaban, edoxaban, and then dabigatran.
Recommendation
All economic studies in this review were not based on head-to-
head clinical sources of data. They were based on the data
obtained from the phase 3 clinical trials for each DOAC, when
compared against warfarin. Thus, future head-to-head clinical
studies among DOACs are recommended.
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